Press Release
Oncotarget | Sphingomyelin phosphodiesterase 3 methylation and silencing in oral squamous cell carcinoma results in increased migration and invasion and altered stress response
FOR IMMEDIATE RELEASE
2020-02-07
Oncotarget Volume 11 Issue 5: While lentivirus-induced overexpression of SMPD3 in cell models of oral dysplasia and OSCC did not significantly alter proliferation, it did decrease migration and invasion and increased resistance to the epidermal growth factor receptor inhibitor erlotinib.
These results suggest that SMPD3 downregulation is a common event in OSCC progression and may promote the spread of tumor cells.
Dr. Cathie Garnis from the Department of Integrative Oncology at British Columbia Cancer Research Centre as well as the Division of Otolaryngology at the Department of Surgery at the University of British Columbia said in their Oncotarget Research Article, "Oral squamous cell carcinoma (OSCC) is among the most commonly diagnosed cancer types in the world, with over 300,000 new cases and 145,000 deaths attributed to the disease worldwide each year."
Ceramide plays a complex role in the cell by altering the composition of lipid rafts and impinging on various signaling pathways.
Initial studies on the role of ceramide found that it induced apoptosis and inhibited the cell cycle in leukemic cells, suggesting a tumor-suppressive role.
For instance, ceramide accumulation following nSMase2 activation that was triggered by oxidative stress resulted in apoptosis of human airway epithelial cells, whereas activation of the same enzyme protected neuroblastoma cells from nutrient deprivation-induced cell death.
NSMase2-mediated generation of ceramide may be further influenced by the expression of other ceramide-metabolizing enzymes, such as ceramidases, ceramide kinase and glucosyltransferase, and enzymes involved in de novo ceramide synthesis.
Thus, the role of nSMase2 is context-dependent and has not been examined in OSCC cells.
The Garnis research team concluded in their Oncotarget paper, "we have identified the promoter region of SMPD3 as a common site of hypermethylation and downregulation in oral tumors and in oral dysplasia and cancer cell lines."
Our experiments suggest that SMPD3 regulates the migratory capacity of tumors cells and can alter their response to EGFR-targeted therapy.
Sign up for free Altmetric alerts about this article
Full text - https://doi.org/10.18632/oncotarget.27458
Correspondence to - Cathie Garnis - cgarnis@bccrc.ca
Keywords - oral squamous cell carcinoma, DNA methylation, SMPD3, erlotinib, cancer progression
Copyright © 2024 Impact Journals, LLC
Impact Journals is a registered trademark of Impact Journals, LLC